关注
Xiaosai Yao
Xiaosai Yao
在 gene.com 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
J Zhang, T Wu, J Simon, M Takada, R Saito, C Fan, XD Liu, E Jonasch, ...
Science 361 (6399), 290-295, 2018
1482018
VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ...
Cancer discovery 7 (11), 1284-1305, 2017
1392017
Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity
WF Ooi, M Xing, C Xu, X Yao, MK Ramlee, MC Lim, F Cao, K Lim, D Babu, ...
Nature communications 7 (1), 12983, 2016
1362016
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma
ML Nairismägi, ME Gerritsen, ZM Li, GC Wijaya, BKH Chia, Y Laurensia, ...
Leukemia 32 (5), 1147-1156, 2018
642018
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits
X Yao, AD Choudhury, YJ Yamanaka, VA Adalsteinsson, TM Gierahn, ...
Integrative Biology 6 (4), 388-398, 2014
532014
Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma
A Qamra, M Xing, N Padmanabhan, JJT Kwok, S Zhang, C Xu, YS Leong, ...
Cancer discovery 7 (6), 630-651, 2017
522017
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
TJ Hagenbeek, JR Zbieg, M Hafner, R Mroue, JA Lacap, NM Sodir, ...
Nature Cancer 4 (6), 812-828, 2023
482023
Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma
WF Ooi, AM Nargund, KJ Lim, S Zhang, M Xing, A Mandoli, JQ Lim, ...
Gut 69 (6), 1039-1052, 2020
482020
HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer
C Xu, WF Ooi, A Qamra, J Tan, BYJ Chua, SWT Ho, K Das, ZFA Isa, Z Li, ...
Gut 69 (2), 231-242, 2020
402020
CD8+ Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti‐tumor response
DT Le, BH Ladle, T Lee, V Weiss, X Yao, A Leubner, TD Armstrong, ...
International journal of cancer 129 (3), 636-647, 2011
312011
Tumor cells are dislodged into the pulmonary vein during lobectomy
X Yao, C Williamson, VA Adalsteinsson, RS D'Agostino, T Fitton, ...
The Journal of thoracic and cardiovascular surgery 148 (6), 3224-3231. e5, 2014
252014
Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells
X Yao, M Labelle, CR Lamb, JM Dugan, CA Williamson, DR Spencer, ...
International journal of cancer 133 (12), 2925-2933, 2013
222013
Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokines
VA Adalsteinsson, N Tahirova, N Tallapragada, X Yao, L Campion, ...
Integrative Biology 5 (10), 1272-1281, 2013
202013
Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer
M Xing, WF Ooi, J Tan, A Qamra, PH Lee, Z Li, C Xu, N Padmanabhan, ...
The Journal of clinical investigation 130 (6), 3005-3020, 2020
172020
RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer
P Deng, Z Wang, J Chen, S Liu, X Yao, S Liu, L Liu, Z Yu, Y Huang, ...
The Journal of Clinical Investigation 132 (22), 2022
142022
VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017; 7: 1284–1305. doi: 10.1158/2159-8290
X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ...
CD-17-0375.[Abstract][CrossRef][Google Scholar], 0
13
Chromatin rewiring by mismatch repair protein MSH2 alters cell adhesion pathways and sensitivity to BET inhibition in gastric cancer
AM Nargund, C Xu, A Mandoli, A Okabe, GB Chen, KK Huang, T Sheng, ...
Cancer Research 82 (14), 2538-2551, 2022
102022
Transcriptional regulation of the Hippo pathway: current understanding and insights from single-cell technologies
S Paul, S Xie, X Yao, A Dey
Cells 11 (14), 2225, 2022
102022
Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer
S Liu, Q Zou, JP Chen, X Yao, P Guan, W Liang, P Deng, X Lai, J Yin, ...
The Journal of Clinical Investigation 131 (20), 2021
102021
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
J Liang, ER Ingalla, X Yao, BE Wang, L Tai, J Giltnane, Y Liang, ...
Science Translational Medicine 14 (663), eabo5959, 2022
82022
系统目前无法执行此操作,请稍后再试。
文章 1–20